Option chain shows key data for Hepion Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hepion Pharmaceuticals.

Hepion Pharmaceuticals (OTC:HEPA) Stock, Option Chain

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

PATH

SGBX

SNES

STGW

YOSH

Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

abbott shutter

Earnings

Equities

Eurozone

Commodities

Intraday Update

ABSI

AGYS

BLBX

LSTA

Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Inc

Press Releases

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Health Care

General

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Hepion Pharmaceuticals Announces Reverse Stock Split

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell